SCHEMBL4088693

SCHEMBL4088693

CC1CCCC(C)N1CCO

nearest known ligand 0.41

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.38
MGLL Q99685 1/20 0.37
HRH3 Q9Y5N1 2/20 0.35
HRH2 P25021 1/20 0.35
HRH1 P35367 1/20 0.35
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8237729 1.00 LTA4H (0.38) LTA4HMGLLHRH3HRH2HRH1
SCHEMBL4079655 1.00 LTA4H (0.38) LTA4HMGLLHRH3HRH2HRH1
SCHEMBL12371257 0.90 OPRM1 (0.33) HRH3HRH2HRH1
SCHEMBL4084781 0.90 OPRM1 (0.33) HRH3HRH2HRH1
SCHEMBL5789637 0.88 CYP1A2 (0.35) LTA4HHRH3MAOB
SCHEMBL10867797 0.88 ACHE (0.45)
SCHEMBL4089544 0.86 HRH3 (0.40) HRH3HRH2HRH1MAOB
SCHEMBL4089546 0.86 HRH3 (0.40) HRH3HRH2HRH1MAOB
SCHEMBL10469227 0.84 HRH3 (0.39) HRH3HRH2HRH1MAOB
Iodide SCHEMBL5786537 0.82 HRH3 (0.41) HRH3HRH2HRH1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12384789-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2025-08-12 US disclosed
EP-3634953-B1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2024-01-03 EP disclosed
EP-4151627-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2023-03-22 EP disclosed
WO-2022204471-A1 REGULATION OF TRANSGENE EXPRESSION USING A SMALL MOLECULE INDUCIBLE SPLICING SWITCH PTC THERAPEUTICS INC. (US) 2022-09-29 WO disclosed
US-20220251098-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2022-08-11 US disclosed
US-11407753-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2022-08-09 US disclosed
US-20200165256-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2020-05-28 US disclosed
CN-111065626-A Compounds for the treatment of huntington's chorea PTC医疗公司 2020-04-24 CN disclosed
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same KIRIN BEER KABUSHIKI KAISHA (JP) 2008-08-28 US disclosed
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same KIRIN BEER KABUSHIKI KAISHA (JP) 2008-08-28 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed
US-4599090-A TERTIARY AMINE ETHER THE LUBRIZOL CORPORATION (US) 1986-07-08 US disclosed
US-4477362-A FROM AN ALIPHATIC ALCOHOL AND A TERTIARY AMINO ALCOHOL THE LUBRIZOL CORPORATION (US) 1984-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251098-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, FH LTA4H 2970/4885MGLL 1699/4885HRH3 1235/4885
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 LTA4H 2426/4885MGLL 3916/4885HRH3 2504/4885
US-20200165256-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, FH LTA4H 2970/4885MGLL 1699/4885HRH3 1235/4885
US-11407753-B2 Compounds for treating Huntington's disease HTT, HYPK, FH LTA4H 2970/4885MGLL 1699/4885HRH3 1235/4885
US-12384789-B2 Compounds for treating Huntington's disease HTT, HYPK, FH LTA4H 2970/4885MGLL 1699/4885HRH3 1235/4885
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same FLT3, TYRO3, ABL1 LTA4H 3677/4885MGLL 1977/4885HRH3 39/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 LTA4H 2448/4885MGLL 3935/4885HRH3 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.